Dialysis News and Research RSS Feed - Dialysis News and Research

When your kidneys are healthy, they clean your blood. They also make hormones that keep your bones strong and your blood healthy. When your kidneys fail, you need treatment to replace the work your kidneys used to do. Unless you have a kidney transplant, you will need a treatment called dialysis.

There are two main types of dialysis: hemodialysis and peritoneal dialysis. Both types filter your blood to rid your body of harmful wastes, extra salt and water. Hemodialysis does that with a machine. Peritoneal dialysis uses the lining of your abdomen, called the peritoneal membrane, to filter your blood. Each type has both risks and benefits. They also require that you follow a special diet. Your doctor can help you decide the best type of dialysis for you.
Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. [More]
TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

TVA Medical, Inc., today announced promising results from a clinical study evaluating a novel hemodialysis access technique that has the potential to revolutionize vascular access for patients with chronic kidney disease without the use of traditional open surgery. [More]
DCR representatives to present health-related quality posters at NKF's 2015 Spring Clinical Meeting

DCR representatives to present health-related quality posters at NKF's 2015 Spring Clinical Meeting

DaVita Clinical Research, a specialty contract research organization with services spanning the full spectrum of drug and device development and subsidiary of DaVita HealthCare Partners Inc., today announced that company representatives will present health-related quality posters at National Kidney Foundation's 2015 Spring Clinical Meeting, which takes place March 25-29, 2015 in Dallas. [More]
Testing APOL1 gene variants in deceased kidney donors may improve transplant outcomes

Testing APOL1 gene variants in deceased kidney donors may improve transplant outcomes

Kidney transplantation outcomes from deceased African-American donors may improve through rapid testing for apolipoprotein L1 gene (APOL1) renal risk variants at the time of organ recovery, according to a new study led by researchers at Wake Forest Baptist Medical Center. [More]
Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid. [More]
DaVita HealthCare Partners named Metro Denver's healthiest extra-large employer

DaVita HealthCare Partners named Metro Denver's healthiest extra-large employer

DaVita HealthCare Partners Inc., one of the nation's largest and most innovative health care communities, has been recognized by the Denver Business Journal as Metro Denver's healthiest extra-large employer. This is the fourth consecutive year the company has topped the list because of its commitment to teammate health and wellness. [More]
Study provide new insights into why childhood CKD may worsen to kidney failure

Study provide new insights into why childhood CKD may worsen to kidney failure

Study results published today in the National Kidney Foundation's American Journal of Kidney Diseases provide new insights into why a child's chronic kidney disease (CKD) may worsen to kidney failure. [More]
Astute Medical hails launch of collaborative global initiative to prevent deaths from AKI by 2025

Astute Medical hails launch of collaborative global initiative to prevent deaths from AKI by 2025

Astute Medical, Inc. today hailed the launch of a collaborative global initiative calling for the elimination of preventable deaths from acute kidney injury (AKI) by 2025. The Company cited the publication of a new Commission from The Lancet and the International Society of Nephrology, along with the release of results from the 0by25 AKI "Global Snapshot" study, as key steps forward in the effort to reduce the global burden of AKI. [More]
Lancet study: Most people lack access to life-saving treatments for kidney failure

Lancet study: Most people lack access to life-saving treatments for kidney failure

New estimates published in The Lancet indicate that at best only half of people worldwide needing kidney dialysis or transplantation to treat kidney failure in 2010 received it. This suggests that at least 2.3 million people may have died prematurely from kidney failure because they could not access this life-saving treatment. [More]
Medical experts aim to offer lifesaving treatments to eliminate preventable deaths from AKI by 2025

Medical experts aim to offer lifesaving treatments to eliminate preventable deaths from AKI by 2025

Preventable deaths caused by acute kidney injury (AKI) could be nearly eliminated in just 10 years, according to leading medical experts. This often forgotten condition - which affects around 13 million people every year and contributes to 1.7 million deaths annually - is preventable and can be treated for as little as $US150 per patient. [More]
Penn researcher named a recipient of 2015 Paul Ehrlich and Ludwig Darmstaedter Prize

Penn researcher named a recipient of 2015 Paul Ehrlich and Ludwig Darmstaedter Prize

University of Pennsylvania cancer and HIV expert Carl June, MD, has been named one of two recipients of the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize for his outstanding work in cancer immunotherapy. Since 1952, the Paul Ehrlich and Ludwig Darmstaedter Prize has been awarded to scientists who have made great advancements in the fields in which Paul Ehrlich worked, in particular immunology, cancer research, microbiology, and chemotherapy. [More]
Apollo signs license option deal with Case Western to develop point-of-care blood analyzer

Apollo signs license option deal with Case Western to develop point-of-care blood analyzer

A blood test yields a wealth of information crucial to a person's health. What's needed is a device that is small and inexpensive, yet capable of quickly providing a thorough analysis using a very small sample. [More]
EMA's CHMP backs JINARC (tolvaptan) for autosomal dominant polycystic kidney disease

EMA's CHMP backs JINARC (tolvaptan) for autosomal dominant polycystic kidney disease

Otsuka Pharmaceutical Co., Ltd. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended JINARC (tolvaptan) for approval. [More]
New medical device could revolutionise kidney disease care in the UK

New medical device could revolutionise kidney disease care in the UK

A new medical device which combines nanotechnology with a pregnancy tester could help diagnose and treat the 1 million people in the UK who don’t know they have kidney disease, a new report by the Institution of Mechanical Engineers reveals today. [More]
Diets high in animal proteins can worsen progression of kidney disease

Diets high in animal proteins can worsen progression of kidney disease

An estimated 26 million people in the United States have chronic kidney disease, which can lead to complete kidney failure. Once the kidneys fail, patients either need to undergo dialysis treatments three times a week or have a kidney transplant to remain alive. [More]
EKF introduces new diabetic biomarker test – The Stanbio Chemistry GSP LiquiColor® Assay

EKF introduces new diabetic biomarker test – The Stanbio Chemistry GSP LiquiColor® Assay

Glycated Serum Protein bridges the gap in diabetes testing in cases where HbA1c cannot be reliably measured [More]
Study results pave way for new clinical trial for glioblastoma patients

Study results pave way for new clinical trial for glioblastoma patients

Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research. [More]
Elsevier chosen to publish ISN's Kidney International and Kidney International Supplements journals

Elsevier chosen to publish ISN's Kidney International and Kidney International Supplements journals

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the International Society of Nephrology, the global medical society devoted to advancing kidney care worldwide, announced today that Elsevier will publish ISN's flagship journals, Kidney International and Kidney International Supplements, as of January 1, 2016. [More]
Elsevier to publish ISN's flagship journals, Kidney International and Kidney International Supplements

Elsevier to publish ISN's flagship journals, Kidney International and Kidney International Supplements

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the International Society of Nephrology (ISN), the global medical society devoted to advancing kidney care worldwide, announced today that Elsevier will publish ISN's flagship journals, Kidney International and Kidney International Supplements, as of January 1, 2016. [More]
MJC ICM works out general guidelines for intensive care medicine

MJC ICM works out general guidelines for intensive care medicine

Frankfurt-based intensive care medical practitioner, Kai Zacharowski, is working on a joint curriculum for Europe. [More]
Advertisement
Advertisement